In one of the first rulings to apply the U.S. Supreme Court’s new “nerve center” test for determining corporate citizenship, a federal judge has ruled that since GlaxoSmithKline’s executive headquarters is in Philadelphia, the company cannot remove a products liability lawsuit from a Pennsylvania state court to federal court.
“As a citizen of Pennsylvania, GSK violated 28 U.S.C. Section 1441(b) when it removed this case from the Philadelphia County Court of Common Pleas,” U.S. District Judge J. Curtis Joyner wrote in his nine-page opinion in Monroe v. SmithKline Beecham and GlaxoSmithKline (pdf).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
